Evaluation of the oral immunogenicity of M cell-targeted tetravalent EDIII antigen for development of plant-based edible vaccine against dengue infection
- 11 Downloads
Four serotypes of the dengue virus that can cause severe disease in humans greatly increases the complexity of vaccine development. In this study, we evaluated an ‘all-in-one’ tetravalent dengue vaccine candidate as an alternative to the classical four viruses ‘cocktail’ vaccination approach. A single polypeptide chain of the tetra-EDIII comprising all four serotypes fused to the M-cell target ligand peptide (tEDIII-Co1) was constructed and expressed using a rice expression system under the control of a strong inducible promoter (rice amylase 3D: Ramy3D) and rice 3′ untranslated region (UTR). The tEDIII-Co1 was constructed using wild type or plant codon optimized gene sequence to compare the expression levels. The codon optimized gene combined with ER-localization showed higher and more stable expression than codon-optimization alone or the wild type. To test the oral immunogenicity of this construct, the transgenic rice cells containing 100 µg of tEDIII-Co1 were fed to mice and the antigen specific IgG and IgA antibodies analysed in sera or fecal extracts. The tEDIII fused to Co1 induced strong antibody responses in the absence of any adjuvants. We observed the strongest antigen-specific B and T cell responses in animals immunized with tEDIII-Co1. Taken together, this simple tetravalent EDIII-based fusion protein with the M cell ligand could has potential as an alternative dengue vaccine strategy against all four serotypes.
KeywordsOral immunogenicity Tetravalent vaccine Dengue Transgenic rice M cell ligand
This study was supported by NRF-2014K1B1A1073861 through the National Research Foundation (NRF) funded by the Korean Ministry of Science, ICT & Future Planning, Republic of Korea.
M-Y K. conceived and designed the overall study. M-Y K. and B-Y K performed the experiments and co-wrote the manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare no conflict of interest.
- Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI (2013) The global distribution and burden of dengue. Nature 496(7446):504–507. https://doi.org/10.1038/nature12060 CrossRefGoogle Scholar
- Brady OJ, Gething PW, Bhatt S, Messina JP, Brownstein JS, Hoen AG, Moyes CL, Farlow AW, Scott TW, Hay SI (2012) Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoS Negl Trop Dis 6(8):e1760. https://doi.org/10.1371/journal.pntd.0001760 CrossRefGoogle Scholar
- Gonzalez-Rabade N, McGowan EG, Zhou F, McCabe MS, Bock R, Dix PJ, Gray JC, Ma JK (2011) Immunogenicity of chloroplast-derived HIV-1 p24 and a p24-Nef fusion protein following subcutaneous and oral administration in mice. Plant Biotechnol J 9(6):629–638. https://doi.org/10.1111/j.1467-7652.2011.00609.x CrossRefGoogle Scholar
- Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, Muhammad Ismail HI, Reynales H, Limkittikul K, Rivera-Medina DM, Tran HN, Bouckenooghe A, Chansinghakul D, Cortes M, Fanouillere K, Forrat R, Frago C, Gailhardou S, Jackson N, Noriega F, Plennevaux E, Wartel TA, Zambrano B, Saville M (2015) Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 373(13):1195–1206. https://doi.org/10.1056/NEJMoa1506223 CrossRefGoogle Scholar
- Kanesa-thasan N, Sun W, Kim-Ahn G, Van Albert S, Putnak JR, King A, Raengsakulsrach B, Christ-Schmidt H, Gilson K, Zahradnik JM, Vaughn DW, Innis BL, Saluzzo JF, Hoke CH Jr (2001) Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 19(23–24):3179–3188CrossRefGoogle Scholar
- Kim MY, Kim BY, Oh SM, Reljic R, Jang YS, Yang MS (2016) Oral immunisation of mice with transgenic rice calli expressing cholera toxin B subunit fused to consensus dengue cEDIII antigen induces antibodies to all four dengue serotypes. Plant Mol Biol 92(3):347–356. https://doi.org/10.1007/s11103-016-0517-0 CrossRefGoogle Scholar
- Kim MY, Van Dolleweerd C, Copland A, Paul MJ, Hofmann S, Webster GR, Julik E, Ceballos-Olvera I, Reyes-Del Valle J, Yang MS, Jang YS, Reljic R, Ma JK (2017) Molecular engineering and plant expression of an immunoglobulin heavy chain scaffold for delivery of a dengue vaccine candidate. Plant Biotechnol J 15(12):1590–1601. https://doi.org/10.1111/pbi.12741 CrossRefGoogle Scholar
- Kim MY, Copland A, Nayak K, Chandele A, Ahmed MS, Zhang Q, Diogo GR, Paul MJ, Hofmann S, Yang MS, Jang YS, Ma JK, Reljic R (2018a) Plant-expressed Fc-fusion protein tetravalent dengue vaccine with inherent adjuvant properties. Plant Biotechnol J 16(7):1283–1294. https://doi.org/10.1111/pbi.12869 CrossRefGoogle Scholar
- Kim SH, Kim YN, Kim J, Jang YS (2018b) C5a receptor targeting of partial non-structural protein 3 of dengue virus promotes antigen-specific IFN-gamma-producing T-cell responses in a mucosal dengue vaccine model. Cell Immunol 325:41–47. https://doi.org/10.1016/j.cellimm.2018.01.016 CrossRefGoogle Scholar
- Ma S, Wang L, Huang X, Wang X, Chen S, Shi W, Qiao X, Jiang Y, Tang L, Xu Y, Li Y (2018) Oral recombinant Lactobacillus vaccine targeting the intestinal microfold cells and dendritic cells for delivering the core neutralizing epitope of porcine epidemic diarrhea virus. Microb Cell Fact 17(1):20. https://doi.org/10.1186/s12934-018-0861-7 CrossRefGoogle Scholar